Cerebral rituximab uptake in multiple sclerosis: A (89)Zr-immunoPET pilot study

Previous studies have demonstrated that the chimeric monoclonal antibody rituximab significantly reduces clinical and radiological disease activity in relapsing-remitting multiple sclerosis as early as 4 weeks after the first administration. The exact mechanisms leading to this rapid effect have not...

Descripción completa

Detalles Bibliográficos
Autores principales: Hagens, Marloes HJ, Killestein, Joep, Yaqub, Maqsood M, van Dongen, Guus AMS, Lammertsma, Adriaan A, Barkhof, Frederik, van Berckel, Bart NM
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2017
Materias:
Short Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5891689/
https://www.ncbi.nlm.nih.gov/pubmed/28443358
http://dx.doi.org/10.1177/1352458517704507
Descripción
Sumario:Previous studies have demonstrated that the chimeric monoclonal antibody rituximab significantly reduces clinical and radiological disease activity in relapsing-remitting multiple sclerosis as early as 4 weeks after the first administration. The exact mechanisms leading to this rapid effect have not yet been clarified. The aim of this positron emission tomography study was to assess central nervous system penetration as a possible explanation, using zirconium-89-labelled rituximab. No evidence was found for cerebral penetration of [(89)Zr]rituximab.

Ejemplares similares